Intro

This chapter explores the newly approved migraine medication Simbravo, which combines risotriptan and meloxicam to provide swift relief. The speakers discuss its clinical trial outcomes, effectiveness versus placebo, and the hurdles encountered during its FDA approval journey.

Play episode from 00:00

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app